Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    2.
    发明申请
    Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists 有权
    吡唑并[4,3-e] -1,2,4-三唑并 - [1,5-c] - 嘧啶腺苷A2a受体拮抗剂

    公开(公告)号:US20050239795A1

    公开(公告)日:2005-10-27

    申请号:US11108916

    申请日:2005-04-19

    IPC分类号: A61K31/519 C07D487/14

    CPC分类号: C07D487/14

    摘要: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

    摘要翻译: 具有结构式I的化合物或其药学上可接受的盐,其中R是任选取代的苯基,呋喃基,噻吩基,吡啶基,吡啶基N-氧化物,恶唑基或吡咯基,或环烯基R 1, R 3,R 3,R 4和R 5是H,烷基或烷氧基烷基; 和Z是任选取代的芳基或杂芳基。 还公开了式I化合物在治疗中枢神经系统疾病,特别是帕金森病中单独使用或与用于治疗帕金森病的其它药物组合的用途,以及包含它们的药物组合物的用途。

    2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    3.
    发明申请
    2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists 有权
    2-炔基 - 和2-烯基 - 吡唑并[4,3-e] -1,2,4-三唑并 - [1,5-c] - 嘧啶腺苷A2a受体拮抗剂

    公开(公告)号:US20050222164A1

    公开(公告)日:2005-10-06

    申请号:US11135261

    申请日:2005-05-23

    CPC分类号: C07D487/14

    摘要: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

    摘要翻译: 具有结构式I的化合物或其药学上可接受的盐,其中R是R 1,R 2,R 3,R 3, 4和R 5是H,烷基或烷氧基烷基; R 6是H,烷基,羟基烷基或-CH 2 F; R 7,R 8和R 9是H,烷基,烷氧基,烷硫基,烷氧基烷基,卤素或-CF 3, SUB>; 和Z是任选取代的芳基,杂芳基或杂芳基 - 烷基。 还公开了式I化合物在治疗中枢神经系统疾病,特别是帕金森病中单独使用或与用于治疗帕金森病的其它药物组合的用途,以及包含它们的药物组合物的用途。

    Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11β-hydroxysteroid dehydrogenase type-1
    7.
    发明授权
    Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11β-hydroxysteroid dehydrogenase type-1 有权
    用于抑制1型11β-羟类固醇脱氢酶的二取代的双环哌啶基和哌嗪基 - 磺酰胺

    公开(公告)号:US08604195B2

    公开(公告)日:2013-12-10

    申请号:US12672825

    申请日:2008-08-12

    CPC分类号: C07D451/04 C07D491/08

    摘要: In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.

    摘要翻译: 在其许多实施方案中,本发明涉及一类新颖的取代的双环哌啶基和哌嗪基磺酰胺化合物,其可用于抑制含有该化合物的11β-羟类固醇脱氢酶I型药物组合物,以及治疗,预防,抑制或改善 与使用这些化合物或药物组合物的-11β-羟基类固醇脱氢酶I型的表达相关的一个或多个条件。